Articles tagged "Calcineurin"

2019 American Transplant Congress
Cardioprotective Effects of Pre-Operative Cyclosporine in Patients Undergoing Heart Transplantation
Y. Hirase, M. Harris, M. Watson, H. Lee, C. Patel
Duke University Hospital, Durham, NC
*Purpose: The purpose of this study is to determine if pre-operative cyclosporine (Cya) decreases the rate of primary graft dysfunction (PGD) in patients undergoing orthotopic…
2019 American Transplant Congress
Mitochondrial Dysfunction and Metabolic Reprogramming: Critical Features of Cyclosporine A Nephrotoxicity
A. A. Zmijewska, G. Benavides, V. Darley-Usmar, J. W. Zmijewski, R. B. Mannon
University of Alabama at Birmingham, Birmingham, AL
*Purpose: Calcineurin inhibitors (CNIs) are potent immunosuppressants but over time contribute to allograft fibrosis. Clinical efforts to minimize or avoid CNI have not been uniformly…
2019 American Transplant Congress
Calcineurin Inhibitors and Long-Term Outcomes of Kidney Transplantation from Thai Transplant Registry
S. Udomkarnjananun, N. Townamchai, Y. Avihingsanon, K. Praditpornsilpa
Chulalongkorn University, Bangkok, Thailand
*Purpose: Calcineurin inhibitors (CNIs) have became the primary immunosuppressive medications (IS) for kidney transplantation (KT) in the current era. However, the long-term outcomes of KT…
2018 American Transplant Congress
The Study of the Influence on hIAPP Deposition and Dysfunction in INS-1 Cell by Calcineurin Inhibitors
J. Zhang, W. Lv, C. Zhang, N. Sun, X. Li, Y. Shi, A. Jiao, J. Lin, Y. Lv.
Hepatobiliary Surgery Department and Unit of Organ Transplantation, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Background hIAPP is formed in islet β cells, misfolded hIAPP results in the deposition inside the β-cells and shows a damage to the β-cells. The…
2018 American Transplant Congress
Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
A. Leino,¹ C. Emoto,² T. Fukuda,² M. Privitera,¹ A. Vinks,^1,2 R. Alloway.¹
¹University of Cinninati, Cincinnati, OH; ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Cannabidiol (CBD), a major purified non-psychoactive component of marijuana with anticonvulsant properties, is being studied under an expanded access IND as an adjuvant treatment for…
2018 American Transplant Congress
The Effect of Tacrolimus Trough Level and Intrapatient Variability on the Transplant Outcomes in Kidney Transplantation
J. Lee,¹ J. Lee,¹ Y. Jung,¹ D. Kim,¹ S. Song,² J. Lee,³ J. Lee,¹ M. Kim,¹ S. Kim,¹ Y. Kim,¹ B. Kim,⁴ K. Huh.¹
¹Surgery, Yonsei University College of Medicine, Seoul, Korea; ²Surgery, Ewha Womans University, School of Medicine, Seoul, Korea; ³Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Korea; ⁴Internal Medicine (Nephrology), Yonsei University College of Medicine, Seoul, Korea.
Background: Tacrolimus (TAC) is the mainstay of immunosuppression for kidney transplantation (KT). Although TAC has a narrow therapeutic index, appropriate trough concentrations of TAC have…
2018 American Transplant Congress
Once Daily CNI Administration Based on Pharmacodynamic Analysis for Preventing Viral Infection
Y. Matsuoka,¹ K. Iwasaki,² Y. Miwa,² K. Horimi,¹ K. Uchida,² T. Kobayashi.¹
¹Renal Transplant Surgery, Aichi Medical University, Nagakute City, Aichi, Japan; ²Kidney Disease and Transplant Immunology, Aichi Medical University, Nagakute City, Aichi, Japan.
BackgroundInfectious complications under immunosuppressive therapy are inevitable problems. Viral infection (include reactivation) occurs at a certain frequency even if immunosuppressive agents are totally adjusted by…
2018 American Transplant Congress
Presence of Chronic Vascular Lesions on Allograft Biopsy is Associated with Greater Improvement in Renal Function after Conversion from Tacrolimus to Belatacept
M. Perez-Saez,^1,2 B. Yu,¹ A. Uffing,¹ N. Murakami,¹ J. Azzi,¹ S. El Haji,³ S. Gabardi,³ L. Riella.¹
¹Transplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; ²Servicio de Nefrologia, Hospital del Mar, Barcelona, Spain; ³Pharmacy Services, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Background: Conversion from tacrolimus to belatacept has been shown to be beneficial for an increasing number of kidney transplant (KT) patients. However, predicting factors for…
2018 American Transplant Congress
Long Term Outcomes of a Steroid Free, Low Dose Tacrolimus with Everolimus Regimen in Kidney Transplant
Y. Kassis,¹ S. Park,¹ A. Shetty,¹ J. Leventhal,¹ V. Mas,² L. Gallon.¹
¹Comprehensive Transplant Center, Northwestern University, Chicago, IL; ²Department of Surgery, University of Virginia, Charlottesville, VA.
Tacrolimus (Tac) is the most effective immunosuppressive agent to prevent acute allograft rejection. However, long-term transplant (Tx) outcomes are limited, at least in part, by…
2018 American Transplant Congress
Superiority of Early Everolimus-Based Quadruple Immunosuppression versus Standard Triple Therapy after Lung Transplantation: 12 Months Results from Prospective 4EVERLUNG Study in Germany
J. Gottlieb, C. Neurohr, J. Müller-Quernheim, H. Wirtz, B. Sill, H. Wilkens, V. Besa, C. Knosalla, M. Junge, C. Capusan, M. Strüber.
Klinik, Hannover, Germany; Klinik, München, Germany; Klinik, Freiburg, Germany; Klinik, Leipzig, Germany; Klinik, Hamburg, Germany; Klinik, Homburg, Germany; Klinik, Essen, Germany; Klinik, Berlin, Germany; Novartis Pharma, Nürnberg, Germany; Novartis Pharma, Nürnberg, Germany; Klinik, Hannover, Germany.
The 4Everlung trial was designed to evaluate the benefit of early everolimus (EVR)-based quadruple low immunosuppressive (IS) regimen on kidney function (RF) after LTx.4EVERLUNG is…

« Previous Page
1
…
6
7
8
9
10
…
16
Next Page »